Sonic Hedgehog factor Gli1: As good as resistant

Hiba Ahmad Zahreddine; Biljana Culjkovic-Kraljacic; Katherine L.B. Borden

doi:10.4161/23723548.2014.961827

Sonic Hedgehog factor Gli1: As good as resistant

Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Katherine L.B. Borden^*

^*Corresponding author for this work

Pharmacology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Chemoresistance remains a major impediment in cancer therapy. Although major progress has been made in understanding the mechanisms underlying resistance in cancer, there is still more to learn. Our studies provide evidence that Gli1 drives a novel form of drug resistance involving Phase II drug metabolism enzymes, specifically the UGT1A family.

Original language	English (US)
Article number	e961827
Journal	Molecular and Cellular Oncology
Volume	2
Issue number	1
DOIs	https://doi.org/10.4161/23723548.2014.961827
State	Published - Jan 2 2015

Keywords

cancer
cytarabine
drug resistance
eIF4E
Gli1
glucuronidation
ribavirin
UGT1A
Vismodegib

ASJC Scopus subject areas

Molecular Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/23723548.2014.961827

Cite this

@article{7a555775ffcd48fa8692746d91b7a514,

title = "Sonic Hedgehog factor Gli1: As good as resistant",

abstract = "Chemoresistance remains a major impediment in cancer therapy. Although major progress has been made in understanding the mechanisms underlying resistance in cancer, there is still more to learn. Our studies provide evidence that Gli1 drives a novel form of drug resistance involving Phase II drug metabolism enzymes, specifically the UGT1A family.",

keywords = "cancer, cytarabine, drug resistance, eIF4E, Gli1, glucuronidation, ribavirin, UGT1A, Vismodegib",

author = "Zahreddine, {Hiba Ahmad} and Biljana Culjkovic-Kraljacic and Borden, {Katherine L.B.}",

note = "Publisher Copyright: {\textcopyright} 2015, {\textcopyright} 2015 The Author(s). Published with license by Taylor & Francis Group, LLC. {\textcopyright} 2015, {\textcopyright} Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, and Katherine LB Borden.",

year = "2015",

month = jan,

day = "2",

doi = "10.4161/23723548.2014.961827",

language = "English (US)",

volume = "2",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Sonic Hedgehog factor Gli1

T2 - As good as resistant

AU - Zahreddine, Hiba Ahmad

AU - Culjkovic-Kraljacic, Biljana

AU - Borden, Katherine L.B.

PY - 2015/1/2

Y1 - 2015/1/2

N2 - Chemoresistance remains a major impediment in cancer therapy. Although major progress has been made in understanding the mechanisms underlying resistance in cancer, there is still more to learn. Our studies provide evidence that Gli1 drives a novel form of drug resistance involving Phase II drug metabolism enzymes, specifically the UGT1A family.

AB - Chemoresistance remains a major impediment in cancer therapy. Although major progress has been made in understanding the mechanisms underlying resistance in cancer, there is still more to learn. Our studies provide evidence that Gli1 drives a novel form of drug resistance involving Phase II drug metabolism enzymes, specifically the UGT1A family.

KW - cancer

KW - cytarabine

KW - drug resistance

KW - eIF4E

KW - Gli1

KW - glucuronidation

KW - ribavirin

KW - UGT1A

KW - Vismodegib

UR - http://www.scopus.com/inward/record.url?scp=85051785576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051785576&partnerID=8YFLogxK

U2 - 10.4161/23723548.2014.961827

DO - 10.4161/23723548.2014.961827

M3 - Article

C2 - 27308395

AN - SCOPUS:85051785576

SN - 2372-3556

VL - 2

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 1

M1 - e961827

ER -

Sonic Hedgehog factor Gli1: As good as resistant

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this